title: Ebola vaccines - Where are we?
abstract: The 2014-16 Ebola outbreak in West Africa has by far been the largest and most devastating Ebola outbreak so far. At the start of the epidemic only 2 Ebola DNA vaccine candidates had been tested in clinical trials and the correlate of protection in humans was unknown. International stakeholders coordinated by the World Health Organization agreed to fast-track the development of 2 Ebola vaccine candidates, based on adenovirus and vesicular stomatitis virus (VSV) vectors. Phase I and II clinical trials were initiated in the autumn of 2014 and found both vaccines to be acceptable for proceeding to phase III trials. Despite the epidemic waning in the spring of 2015, by July 2015 preliminary results from a phase III trial in Guinea proved the Ebola VSV vaccine to be effective.
authors.affiliation: a Domain for Infection Control and Environmental Health, Norwegian Institute of Public Health , Oslo , Norway.
authors.forename: Sara Viksmoen
authors.initials: SV
authors.lastname: Watle
authors.affiliation: a Domain for Infection Control and Environmental Health, Norwegian Institute of Public Health , Oslo , Norway.
authors.forename: Gunnstein
authors.initials: G
authors.lastname: Norheim
authors.affiliation: a Domain for Infection Control and Environmental Health, Norwegian Institute of Public Health , Oslo , Norway.
authors.forename: John-Arne
authors.initials: JA
authors.lastname: Røttingen
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D055808:Drug Discovery / Q000639:trends*; D046129:Ebola Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control*; D006801:Humans
chemical_list: D046129:Ebola Vaccines
keywords: Ebola viral disease; West Africa; efficacy trial; vaccine; vesicular stomatitis virus